Vanda Pharmaceuticals Reports Fourth Quarter 2017 and Full Year 2017 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/6/2026
- Wall Street climbs as Broadcom and other chipmakers rally
- Oil prices little changed as Saudi cuts prices, OPEC+ boosts target
- Broadcom stock pops 4% as Apple silicon deal gets extended through 2031
- Buy the pullback in chip stocks, JPM's Matejka says
- Memory stocks rebound as analysts flag a buying opportunity
- Nokia OYJ (NOKIA:FH) (NOK) PT Raised to EUR14 at Kepler Cheuvreux
- Dara Khosrowshahi steps down from Grab Holdings board
- Broadcom secures role as key Apple supplier with chip deal through 2031
- Wall Street climbs as Broadcom and other chipmakers rally
- Mahindra & Mahindra Ltd (MM:IN) (MAHMF) PT Raised to INR320 at HSBC
Vanda Pharmaceuticals (VNDA) Tops Q4 EPS by 15c
February 14, 2018 4:03 PM ESTVanda Pharmaceuticals (NASDAQ: VNDA) reported Q4 EPS of $0.03, $0.15 better than the analyst estimate of ($0.12). Revenue for the quarter came in at $44.3 million versus the consensus estimate of $43.45 million.
Sees combined net product sales from both HETLIOZ® and Fanapt® $180 to $200 million
For earnings history and... More
